<DOC>
	<DOCNO>NCT00824161</DOCNO>
	<brief_summary>The purpose study evaluate progression free survival primarily . The secondary objective evaluate antitumor activity , assess objective tumor response , duration clinical benefit , overall survival , safety profile TAS-109</brief_summary>
	<brief_title>Phase II Study TAS-109 Treat Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma Received prior therapy , least two regimen , contain fluoropyrimidine , oxaliplatin , irinotecan Have least one measurable tumor , defined RECIST Must capable maintain central venous line access Had previous antitumor therapy 3 week prior study entry Have recover toxicity ( exclude alopecia ) prior therapy baseline â‰¤grade 1 prior study entry Have another malignancy past 3 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>